Supporting translational research

research_translational_researchjpg

The CRUK Imperial Centre was established to help accelerate the translation of lab-based researched and discoveries into the clinical setting, so that the scientific research undertaken at Imperial College London can directly benefit cancer patients. To this end, the CRUK Imperial Centre is focused on developing research at the convergence of the life, clinical, engineering and physical sciencesWith two broad themes – Reducing the Burden of Cancer and Increasing the Precision of Cancer Treatments – the mission of the CRUK Centre is to develop novel technologies and methodologies that address challenges in the prevention, detection and treatment of cancer. 

If you would like to discuss your translational research project and ideas, or how the CRUK Imperial Centre might be able to help facilitate your research, please contact our Translational Research Funding Manager, Dr Mark Gurden (m.gurden@imperial.ac.uk). 

Supporting Translational Research 

 

CRUK Imperial Centre Development Fund 

The CRUK imperial Centre has an annual Development Fund of £100k to support the early development of novel collaborative projects in convergence science. The intention is to provide seed funding to develop the preliminary data required to build a more substantive project that could attract further funding from external sources. 

Applications will be considered in any cancer related area, providing the applicants can clearly articulate the clinical and/or biological question that project will look to address and how the novel collaborative approach will look to solve this problem. 

Please contact Dr Mark Gurden for more information (m.gurden@imperial.ac.uk).  

 

The Imperial Experimental Cancer Medicine Centre (ECMC) 

The Experimental Cancer Medicine Centres are an initiative jointly supported by Cancer Research UK and the Departments of Health for England, Scotland, Wales and Northern Ireland. The centres use the money they receive to run early phase trials of new and experimental treatments, as well as analyse blood and tissue samples (biopsies) to help find out more about how treatments work and what happens to cancer cells. 

The Imperial ECMC is jointly led by Professor Michael Seckl and Professor Eric AboagyeIts specific objectives are to develop novel imaging, biomarker and therapeutic approaches that will aid in the diagnosis of cancer and deliver better personalised treatments, through harnessing our world-class expertise in Physics, Chemistry and Engineering 

The Imperial College ECMC has established the Imperial Cancer Biomarker Resource Centre (ICBRC), supported by funding from CRUK and the NIHR Imperial BRC, which is able to provide infrastructure support to cancer researchers through: 

  • Quality assured sample collection involving early phase trials and clinical studies  
  • Evaluatingand validating biomarkers using a range of technology platforms including genomic, epigenomic, proteomic and metabolomics  
  • The visualisation and characterisation of tumours through Imaging technologies  
  • Providing bioinformatic and biostatistical analysis  
  • Providing biospecimen samples (either paraffin and fresh-frozen), which can be requested from the ICBRC for proof of concept studies 

If you would like more information on what services could be provided for your research project, please contact the ECMC Centre Manager, Naina Panel (naina.patel@imperial.ac.uk).

 

Clinical Trials 

Clinical studies can also be supported through Imperial Cancer Clinical Trials Section (CCTS)The CCTS provides a comprehensive service to support clinical principal investigators in the process of clinical trial development, from concept and trial design, through to statistical support, application preparation, application submission and trial set-up. 

Please contact the clinical trials manager, Philip Badman, to further discuss potential support for cancer clinical trials p.badman@imperial.ac.uk. 

The Imperial Early Phase Cancer Trials unit also provides facilities to conduct early phase and experimental medicine clinical trials and studies across all solid tumour types. The NIHR Imperial Clinical Research Facility has state of the art facilities to support grant funded Phase 1/11 trials, which includes:  

  • 15 dedicated in-patient beds (including one gene therapy and two negative pressure rooms) and 9 recliners. Telemetry-linkage to all beds. 
  • 5 consulting and 2 interview rooms 
  • Labs and expertise to prepare: PK samples, Dry blood spots, Hair follicles, Skin biopsies, Circulating Tumour Cells, Tumour biopsies 
  • Onsite access to imaging including: Spiral CT, MRI (volumetric assessment), DCE-MRI, DCE/ microbubble Ultrasound, PET/MR, PET/CT. 

All researchers from Imperial College London and Imperial College Healthcare NHS Trust are welcome to apply to run a study within the Clinical Research Facility.